Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-12. (Canceled)

13. (Currently amended) A method of prevention and/or treatment of a patient's asthma symptoms, the method comprising

(i) providing an inhaler to the patient, the inhaler containing a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient which is budesonide; and

(ii) providing a recommendation to the patient to inhale the composition from the inhaler on an as-needed basis, as determined by the patient based on the patient's symptoms, as a treatment and a preventive measure, when the patient experiences an increase in asthma symptoms.

14. (Previously presented) The method according to claim 13, wherein the molar ratio of (a) to (b), calculated as formoterol to budesonide, is from 1:1 to 1:100.

15. (Previously presented) The method according to claim 13, wherein the first active ingredient is formoterol fumarate dihydrate.

16. (Previously presented) The method according to claim 13, wherein the first active ingredient is the R,R enantiomer of formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.

17. (Previously presented) The method according to claim 15, wherein the composition is in the form of unit doses, each of which delivers 1 μg to 48 μg of the first active ingredient to the patient, calculated as formoterol fumarate dihydrate.

18. (Previously presented) The method according to claim 15, wherein step (ii) comprises recommending that the patient inhale an amount per day of the composition, including for maintenance therapy, that contains a total of 1 μg to 100 μg of the first ingredient, calculated as formoterol fumarate dihydrate.

19. (Previously presented) The method according to claim 13, wherein the second active ingredient is the 22R epimer of budesonide.

20. (Previously presented) The method according to claim 13, wherein the composition is in the form of unit doses, each of which delivers 20 μg to 1600 μg of budesonide to the patient.

21. (Previously presented) The method according to claim 13, wherein step (ii) comprises recommending that the patient inhale an amount per day of the composition, including for maintenance therapy, that contains a total of 20 μg to 4800 μg of budesonide.

22. (Previously presented) The method according to claim 13, wherein the particle size of the active ingredients (a) and (b) is less than 10 μm.

23. (Previously presented) The method according to claim 13, wherein the composition additionally comprises one or more pharmaceutically acceptable additives, diluents or carriers.

24. (Previously presented) The method according to claim 13, wherein the composition additionally comprises lactose monohydrate.

25. (Previously presented) The method according to claim 14, wherein the molar ratio of (a) to (b), calculated as formoterol to budesonide, is from 1:1 to 1:70.

26. (Previously presented) The method according to claim 17, wherein the composition is in the form of unit doses, each of which delivers 3 μg to 12 μg of the first ingredient to the patient, calculated as formoterol fumarate dihydrate.

27. (Previously presented) The method according to claim 18, wherein step (ii) comprises recommending that the patient inhale an amount per day of the composition, including for maintenance therapy, that contains a total of 2 μg to 60 μg of the first ingredient, calculated as formoterol fumarate dihydrate.

28. (Previously presented) The method according to claim 20, wherein the composition is in the form of unit doses, each of which delivers 50 μg to 400 μg of budesonide to the patient.

29. (Previously presented) The method according to claim 21, wherein step (ii) comprises recommending that the patient inhale an amount per day of the composition, including for maintenance therapy, that contains a total of 30 μg to 3200 μg of budesonide.

30. (Previously presented) The method according to claim 13, further comprising recommending that the patient inhale the composition as a rescue medication.

31. (Previously presented) The method according to claim 13, further comprising recommending that the patient take a second composition comprising a glucocorticosteroid on a regular basis as a maintenance treatment.

32. (Previously presented) The method according to claim 13, further comprising recommending that the patient use the composition as a complement to maintenance treatment of the patient's asthma.

33. (Previously presented) The method according to claim 13, further comprising recommending that the patient inhale an effective amount of the composition as a preventive measure prior to encountering an asthma triggering event.

34. (Previously presented) The method of claim 33, wherein the asthma triggering event is selected from the group consisting of exposure to cold air, exposure to an allergen, exercise, and exposure to a smoky environment.

35. (Currently amended) A method of prevention and/or treatment of a patient's asthma symptoms, the method comprising

(i) providing an inhaler to the patient, the inhaler containing a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient which is budesonide; and

(ii) providing a recommendation to the patient to inhale the composition from the inhaler on an as-needed basis, as determined by the patient based on the patient's symptoms, as a complement to maintenance treatment of the patient's asthma.

36. (Currently amended) A method of prevention and/or treatment of a patient's asthma symptoms, the method comprising

(i) providing an inhaler to the patient, the inhaler containing a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient which is budesonide; and

(ii) providing a recommendation to the patient to inhale the composition from the inhaler on an as-needed basis, as determined by the patient, when the patient is expecting to encounter an asthma triggering event, as a preventative measure.

37. (Canceled)

38. (Previously presented) The method of claim 13, further comprising recommending that the patient use the composition as a complement to maintenance treatment of the patient's asthma.

39-41. (Canceled)

42. (Currently amended) A method of prevention and/or treatment of a patient's asthma symptoms, the method comprising

(i) providing an inhaler to the patient, the inhaler containing a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient which is budesonide; and

(ii) providing a recommendation to the patient to inhale a maintenance dose of the composition from the inhaler and, if the patient experiences acute asthma symptoms, to inhale additional doses as needed for symptomatic relief.

43. (Previously presented) A method of reducing the incidence of acute asthma attacks in a patient, the method comprising

(i) providing an inhaler to the patient, the inhaler containing a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient which is budesonide; and

(ii) providing a recommendation to the patient to inhale the composition from the inhaler on an as-needed basis, as determined by the patient based on the patient's symptoms, as a treatment and to reduce the incidence of acute asthma attacks, when the patient experiences an increase in asthma symptoms.

44. (Previously presented) The method of claim 13, wherein step (i) comprises filling the inhaler's storage compartment with the composition.

45. (Previously presented) The method of claim 35, wherein step (i) comprises filling the inhaler's storage compartment with the composition.

46. (Previously presented) The method of claim 36, wherein step (i) comprises filling the inhaler's storage compartment with the composition.

47. (Previously presented) The method of claim 42, wherein step (i) comprises filling the inhaler's storage compartment with the composition.

48. (Previously presented) The method of claim 43, wherein step (i) comprises filling the inhaler's storage compartment with the composition.

49. (Previously presented) The method of claim 13, wherein the recommendation causes the patient to inhale the composition at a time the patient experiences an increase in asthma symptoms.

50. (Previously presented) The method of claim 35, wherein the recommendation causes the patient to inhale the composition as a complement to maintenance treatment, at a time the patient experiences an increase in asthma symptoms.

51. (Previously presented) The method of claim 36, wherein the recommendation causes the patient to inhale the composition at a time the patient expects to encounter an asthma triggering event, as a preventive measure.

52. (Previously presented) The method of claim 42, wherein the recommendation causes the patient to inhale the composition at a time the patient experiences acute asthma symptoms, and, as a result of the inhaling, the patient experiences symptomatic relief.

53. (Previously presented) The method of claim 43, wherein the recommendation causes the patient to inhale the composition at a time the patient experiences an increase in asthma symptoms, and, as a result of the inhaling, an acute asthma attack is averted.